Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
CareDx, Inc. reported the first quarter ended March 31, 2026 results: revenue $118 million, net income $3 million, EPS $0.05. Guidance raised.
- Period
- the first quarter ended March 31, 2026
- Revenue
- $118 million
- Net income
- $3 million
- EPS
- $0.05
- Guidance
- raised
- Result
- reported results
Exact text from the filing
for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights · Revenue of $118 million, an increase of 39% year-over-year · Testing services revenue of $91 million, an increase of 48% year-over-year, and testing services volume of approximately 54,900, an increase
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CareDx, Inc. entered into Merger Agreement with Naveris, Inc., Nautilus Merger Sub, Inc., and Shareholder Representative Services LLC valued at $160.0 million in cash, subject to certain customary adjustments, and up to $100.0 million in additi (effective 2026-04-28).
- Action
- entry
- Agreement
- merger
- Counterparty
- Naveris, Inc., Nautilus Merger Sub, Inc., and Shareholder Representative Services LLC
- Value
- $160.0 million in cash, subject to certain customary adjustments, and up to $100.0 million in additi
- Effective
- 2026-04-28
Exact text from the filing
On April 28, 2026, CareDx, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Naveris, Inc., a Delaware corporation (“Naveris”), Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Shareholder Representative Services LLC
View on SEC.gov